Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Deffered Revenue (2016 - 2022)

Protalix BioTherapeutics (PLX) has 13 years of Non-Current Deffered Revenue data on record, last reported at $5.9 million in Q2 2022.

  • For Q2 2022, Non-Current Deffered Revenue rose 364.54% year-over-year to $5.9 million; the TTM value through Jun 2022 reached $5.9 million, up 364.54%, while the annual FY2021 figure was $11.8 million, 587.06% up from the prior year.
  • Non-Current Deffered Revenue reached $5.9 million in Q2 2022 per PLX's latest filing, roughly flat from $5.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $61.8 million in Q3 2018 and bottomed at $858000.0 in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $16.6 million, with a median of $9.5 million recorded in 2020.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 94.64% in 2020, then surged 587.06% in 2021.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $33.0 million in 2018, then crashed by 48.59% to $17.0 million in 2019, then plummeted by 89.89% to $1.7 million in 2020, then soared by 587.06% to $11.8 million in 2021, then tumbled by 50.0% to $5.9 million in 2022.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $5.9 million in Q2 2022, $5.9 million in Q1 2022, and $11.8 million in Q4 2021.